finance.yahoo.com/news/...opment-unique-immuno-120010163.html
Formulation will be First Nutraceutical Compound to be Introduced Under Guardion’s Recently Acquired NutriGuard Business Line
San Diego, California, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI) announced the development of a unique proprietary formulation to provide immuno-support and anti-inflammatory benefits targeting the upper respiratory tract. The Company’s efforts are being spearheaded by its recently acquired NutriGuard business line. NutriGuard formulates high-quality, scientifically-credible, condition-specific nutraceuticals designed to supplement consumers’ diets and assist in the prevention and management of an array of diseases and conditions.
This proprietary new product, to be preliminarily labeled acuMMUNE (trademark registration pending), was designed by Guardion’s internal product and technology design team, and is the first product to be introduced by Guardion under the NutriGuard label. The acuMMUNE formulation was designed with the objective of supporting effective immune function – including, in particular, interferon-mediated anti-viral mechanisms – while also mitigating the excessive lung inflammation that can lead to the harsh symptoms and even death caused by severe lung infections associated with certain viral infections.
acuMMUNE will initially be offered in a capsule form and will be available in the United States through the Company’s web-site (www.guardionhealth.com and www.nutriguard.com). The Company is currently in the process of arranging for the manufacture and packaging of acuMMUNE at contract facilities in the United States and expects that this product will be available for sale beginning in approximately April 2020. The Company anticipates that acuMMUNE will also be available for export to various international markets shortly thereafter.
Recently, the coronavirus (2019-nCoV) has developed into a worldwide epidemic, with over 20,000 cases confirmed in China since it was first detected in December 2019, and is a growing risk to global economies. The World Health Organization (WHO) recently declared the coronavirus outbreak a global emergency as it spreads to countries outside of China and the number of infected patients continues to grow.
Michael Favish, Guardion’s Chief Executive Officer, commented, “We believe that this unique product can provide a timely and effective immune response protocol to address respiratory tract symptoms associated with global pandemics.”
